ARTICLE | Company News
Aegerion, Hayman Capital Management endocrine/metabolic news
March 14, 2016 7:00 AM UTC
The U.S. Patent Trial and Appeal Board instituted two inter partes review petitions from hedge fund manager Kyle Bass targeting patents from the University of Pennsylvania that cover Aegerion’s Juxtapid lomitapide. PTAB found that there was a reasonable likelihood that U.S. Patents Nos. 8,618,135 and 7,932,268 could be rendered obvious in the light of prior art. Both patents cover dosing methods to treat hyperlipidemia and hypercholesterolemia. The coalition filed the petitions in September 2015 (see BioCentury Sept. 7, 2015).
The patents are among five covering Juxtapid that are listed in the Orange Book. The ‘135 patent expires in 2025. The ‘268 patent expires in 2027 -- it is the last to expire. ...